Newsstand | Page 23 | Aplastic Anemia and MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

Originally Published: 01/01/2013
Note: This review is based upon a presentation at the 2012 American Society of Hematology (ASH) Annual Meeting, December 7-10 in Atlanta, Georgia.The full abstract may be reviewed on the ASH Annual Meeting Web site. Search by entering the title in the search box. The abstract number is referenced to access the full report. Abstract #424 Guillermo Garcia-Manero, MD1, Steven D. Gore, MD2, Suman Kambhampati, MD3*, Bart L Scott, MD, MS4, Ayalew Tefferi, MD5, Christopher R Cogle, MD6, William Edenfield, MD7*, Joel Hetzer, PhD8*, Keshava Kumar, PhD8* and Barry S. Skikne, MD9 Treatment for...

Infections in myelodysplastic syndromes: a review

Originally Published: 10/31/2012
Infections are a significant cause of morbidity and mortality in patients with MDS accounting for approximately 38% of all deaths in untreated cases, more so than that resulting from MDS progression to acute myeloid leukemia (AML). Although there is accumulating data on the risk factors and types of infections in MDS patients, interpretation of the available data has been challenging. This stems from several reasons and includes data reporting from different sources, year of study, and use of novel treatment regimens in the last decade, and transplant-related immune defects in those...

New therapeutics for myelodysplastic syndromes

Originally Published: 10/31/2012
In recent years, several therapeutic agents have been approved for treatment of patients with myelodysplastic syndromes (MDS), including lenalidomide (Revlimidâ) and the azanucleosides, azacitidine (Vidazaâ) and decitabine (Dacogenâ).  Although these agents represent a significant step forward in the management of MDS, there remains a definitive need for further progress.  In his review, “New therapeutics for myelodysplastic syndromes,” Dr. List outlines the rationale for MDS-directed drug development efforts and describes several emerging agents currently or soon to be studied in clinical...

Prediction of outcomes after allogeneic stem cell transplantation for myelodysplastic syndromes

Originally Published: 09/27/2012
Allogeneic bone marrow transplantation (aBMT; i.e., a bone marrow transplantation whereby the donor is not genetically related to the recipient) is still the only potential cure for MDS patients.  However, an aBMT may cause serious complications, some of which may result in death.  In other cases, MDS will come back.  The aim of this study was to identify patient characteristics that would predict survival in MDS patients after an aBMT. A retrospective study (i.e., a study in which patient’s disease characteristics and history are investigated going back in time) showed that of the many...

Therapy-related Myelodysplastic Syndrome: an analysis of 5 risk models in patients treated with azacitidine

Originally Published: 09/27/2012
Myelodysplastic syndrome (MDS) is a disease mostly associated with old age, however, it can also occur as a complication of anti-cancer treatment, including certain chemotherapies and/or radiation.  This is called therapy-related MDS (t-MDS).  When it happens it is often an aggressive disease and difficult to treat.  MDS is a very heterogeneous group of diseases and to determine what the best treatment option is for a particular patient is challenging.  Doctors are helped in this process by scoring systems that, based on the characteristics of the patient’s disease, help evaluate the...

Specialized technique effective in identifying chromosomal abnormalities, improving prognosis for MDS

Originally Published: 07/31/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6521 To date, the most widely used prognostic classification system for myelodysplastic syndrome (MDS) is the International Prognostic Scoring System (IPSS). The first IPSS was derived from a study published in 1997. The IPSS separates patients into four distinct subgroups based solely on the percentage of bone marrow blasts, cytogenetics (branch of genetics which studies the...

Sapacitibine shows promise for high-risk MDS patients

Originally Published: 07/30/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6520 Myelodysplastic syndrome (MDS) is a heterogeneous disease, with varied options for treatment. These range from supportive care, which includes blood product transfusions and the use of growth factors, to intensive therapy with allogeneic hematopoietic stem cell transplantation (HSCT). Treatment selection should be based on the patient’s age, performance status, and...

European Study of Horse ATG vs. Rabbit ATG for Treatment of Aplastic Anemia

Originally Published: 07/03/2012
Aplastic anemia is a blood disease caused by the destruction of a person’s normal bone marrow cells by specific white blood cells known as T-lymphocytes. One of the treatment options is to give the patient medications that suppress the immune system, specifically the T-lymphocytes. The best immunosuppressive therapy for patients with severe aplastic anemia (sAA) is a combination of anti-thymocyte globulin (ATG) and cyclosporine (CsA). Combining these two drugs results in response rates of 60-75%. Two types of ATG are currently available.  One derived from the horse, known as horse ATG (hATG...

Overview of stem cell transplantation for aplastic anemia

Originally Published: 07/03/2012
Patients with newly diagnosed severe aplastic anemia (sAA) are treated with drugs that suppress the immune system, antithymocyte globulin (ATG) plus cyclosporine (CsA), or an allogeneic hematopoietic stem cell transplantation (Allo-HSCT).  An Allo-HSCT is a type of bone marrow transplant that uses stem cells taken from another person, known as the donor source or source of the graft. The donor can be the patient’s brother or sister.  This is called a “matched sibling or related donor”.  If a patient does not have a matched sibling or related donor, an unrelated individual that shares...

Allogenic stem cell transplantation for older patients with AML and MDS

Originally Published: 06/29/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6529 Myelodysplastic syndrome (MDS) is often a disease of advanced age with a majority of patients over the age of 65 years at the time of their diagnosis. Although some patients with MDS enjoy a long period of time with minimal symptoms or change in their disease, some patients experience a rapid progression to either bone marrow failure or acute myeloid leukemia (AML). For...